Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, et al.
Applied Health Economics and Health Policy (2019) Vol. 18, Iss. 1, pp. 5-16
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Brian Godman, Andrew Hill, Steven Simoens, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2021) Vol. 21, Iss. 4, pp. 527-540
Open Access | Times Cited: 63
Integrative Review of Managed Entry Agreements: Chances and Limitations
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, et al.
PharmacoEconomics (2020) Vol. 38, Iss. 11, pp. 1165-1185
Open Access | Times Cited: 45
Evidence-based public policy making for medicines across countries: findings and implications for the future
Brian Godman, Joseph Fadare, Hye-Young Kwon, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 10, Iss. 12, pp. 1019-1052
Open Access | Times Cited: 36
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
Shai Mulinari, Andreas Vilhelmsson, Emily Rickard, et al.
PLoS ONE (2020) Vol. 15, Iss. 6, pp. e0235021-e0235021
Open Access | Times Cited: 25
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
Alice Pisana, Björn Wettermark, Amanj Kurdi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications
Biljana Tubić, Vanda Marković‐Peković, Saša Jungić, et al.
Medicine Access Point of Care (2021) Vol. 5
Open Access | Times Cited: 11
Introduction of managed entry agreements in Korea: Problem, policy, and politics
Hyungmin Kim, Brian Godman, Hye-Young Kwon, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment
François Girardin, Karen Cohen, Matthias Schwenkglenks, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
Brian Godman, Magdałene Władysiuk, Stuart McTaggart, et al.
BioMed Research International (2021) Vol. 2021, pp. 1-16
Open Access | Times Cited: 9
Goals and methods of managed entry agreements – can we get what we want?
Fanni Ispán, Tamás Hegedűs, Marcell Csanádi, et al.
Health Policy and Technology (2023) Vol. 12, Iss. 2, pp. 100745-100745
Closed Access | Times Cited: 3
Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages
Nenad Miljković, Eline van Overbeeke, Brian Godman, et al.
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 8
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
Adam Raymakers, Kristina Jenei, Dean A. Regier, et al.
PharmacoEconomics (2021) Vol. 39, Iss. 3, pp. 373-377
Closed Access | Times Cited: 7
Budget impact analysis of medicines: estimated values versus real-world evidence and the implications
Daniel Resende Faleiros, Juliana Álvares-Teodoro, Everton Nunes da Silva, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2021) Vol. 22, Iss. 2, pp. 271-281
Open Access | Times Cited: 7
Editorial: Pharmaceutical policy, impact and health outcomes
Hye-Young Kwon, Brian Godman
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 2
Anticancer effects of gingerol, shogaol and curcumin in cervical cancer: A systematic review protocol
Unwaniah Abdull Rahim, Nur Aishah Che Roos, Marami Mustapa, et al.
Advances in Human Biology (2023) Vol. 13, Iss. 3, pp. 246-251
Closed Access | Times Cited: 2
Beschleunigte Zulassung von Arzneimitteln: Herausforderungen für Patient:innen, Datenqualität und faire Preise
Antje Haas, Patrick May, Anja Tebinka-Olbrich, et al.
Springer eBooks (2021), pp. 105-124
Closed Access | Times Cited: 5
The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
Wânia Cristina da Silva, Brian Godman, Francisco de Assis Acúrcio, et al.
Applied Health Economics and Health Policy (2021) Vol. 19, Iss. 4, pp. 557-577
Closed Access | Times Cited: 4
Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care
Ileana Mardare, Stephen Campbell, Johanna C. Meyer, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 3
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Giovanni Tafuri, Chantal Bélorgey, Carlo Favaretti, et al.
International Journal of Technology Assessment in Health Care (2020) Vol. 36, Iss. 3, pp. 191-196
Closed Access | Times Cited: 3
A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England
Nasuh Büyükkaramikli, P. Wigfield, Men Thi Hoang
The European Journal of Health Economics (2020) Vol. 22, Iss. 1, pp. 51-73
Closed Access | Times Cited: 3
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach
Stefano Capri, Fernando Antoñanzas, Rosella Levaggi
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 23, Iss. 4, pp. 431-438
Closed Access | Times Cited: 1
The challenges of access to innovative medicines with limited evidence in the European Union
Antonio Vallano, Caridad Pontes, Antònia Agustí
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 1
Reporting reimbursement price decisions for onco-hematology drugs in Spain
David Elvira, Ferrán Torres, Roser Vives, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 1
Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales
Jessica R. Burton, Kate Halsby, Graciela Sáinz de la Fuente, et al.
PharmacoEconomics (2024)
Open Access
Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
David Elvira, Mercè Obach, Caridad Pontes
BMC Health Services Research (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top